Quest Diagnostics' Fair Value Estimate Increases Amid Strong Performance and Analyst Optimism
ByAinvest
Sunday, Nov 2, 2025 6:20 pm ET1min read
DGX--
Quest Diagnostics' Fair Value Estimate has risen to $197.25 per share, driven by strong quarterly results and positive analyst sentiment. Analysts have raised their price targets, citing solid revenue and volume growth, and momentum in core businesses. However, concerns about valuation and the risk/reward profile have led to some downgrades and negative comments.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet